BioXcel Reports Positive OS Results From Phase 2 Trial Of BXCL701 In Patients With SCNC
BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company focused on neuroscience and immuno-oncology, announced Tuesday positive overall survival or OS data from its Phase 2 trial of BXCL701 in combination with … Read More